Document is current
Any future updates will be listed below
-
Authors
Bonkovsky, Herbert L. https://orcid.org/0000-0001-7387-3230
Rudnick, Sean P.
Ma, Christopher D.
Overbey, Jessica R.
Wang, Kelly
Faust, Denise
Hallberg, Csilla
Hedstrom, Karli
Naik, Hetanshi
Moghe, Akshata
Anderson, Karl E.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03118674 at ClinicalTrials.govDocuments that mention this clinical trial
Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C
https://doi.org/10.1007/s10620-023-07859-8
-
Funding
Funding for this research was provided by:
Gilead Sciences
NIDDK (1 U54 DK083909)
NCATS (5UL1TR001420, UL1RR029876)
- License Information
-
More Information
Article History
Received: 29 November 2022
Accepted: 28 January 2023
First Online: 22 February 2023
Declarations
:
: In the past 3 years, Dr. Bonkovsky has received funding for clinical research studies, awarded to Atrium Wake Forest Baptist Health, from Alnylam Pharmaceuticals, Disc Medicine, Calliditas SA, Gilead Sciences, and Mitsubishi-Tanabe, NA. He has served as a consultant to Alnylam, Disc Medicine, Mitsubishi-Tanabe, and Recordati Rare Chemicals. Dr. Rudnick has served as a consultant to Alnylam Pharmaceuticals; Christopher D. Ma, Jessica Overbey, Kelly Wang, Denise Faust, Csilla Hallberg, and Karli Hedstrom report no potential conflicts; Dr. Naik has served as a consultant to Alnylam Pharmaceuticals, Disc Medicine, Mitsubishi Tanabe, and Recordati Rare Diseases; Dr. Moghe has served as a consultant to Alnylam Pharmaceuticals; Dr. Anderson has received funding for clinical studies, awarded to UTMB, from Mitsubishi-Tanabe, NA and Disc Medicine. He has served as a consultant to and on advisory boards for Alnylam Pharmaceuticals, Mitsubishi-Tanabe, NA, and Recordati Rare Chemicals; the fees for this work have gone to UTMB.
